MABCURE N.V. Signs Research Agreement With AZ Sint Lucas Hospital, Brugge, Belgium, to Conduct Preclinical Research on its Monoclonal Antibodies (Mabs) against Different Cancers.Research Intended to Broaden the Utility of MabCure's Mabs for Cancer Diagnosis in Tissue Specimen HASSELT, Belgium -- MabCure N.V., a subsidiary of MabCure Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: MBCI MBCI Mississippi Band of Choctaw Indians MBCI Member of the Business Continuity Institute MBCI Mennonite Brethren Collegiate Institute (Winnipeg, Manitoba, Canada) MBCI Metal Building Components Inc MBCI Medical Books for China International ), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, has signed a research agreement with AZ Sint Lucas Hospital, Brugge, Belgium. AZ Sint Lucas Hospital will conduct preclinical research intended to broaden the utility of MabCure's monoclonal antibodies for those circumstances where there is a need to diagnose cancer in tissue specimen. At present, the Company's Mabs for the diagnosis of ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast , prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. and colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. , for example, are aimed at diagnosing early stage disease in physiological samples such as urine and serum. Dr. Amnon Gonenne, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of MabCure Inc commented, "If this preclinical research works, it would open a door for us to diagnose everything that goes through surgery. This would include, for example, all of the at-risk melanoma patient population that routinely has moles removed prophylactically. The resection is arbitrary and there is currently no method to determine if the removed moles harbor early stage melanoma or not. This is critically important since melanoma is a highly lethal disease. MabCure's Mabs may provide a definitive diagnosis of early stage melanoma in these tissue specimens thereby allowing effective treatment of the patient. An analogous situation exists in colonoscopy where it is difficult to provide definitive diagnosis of early colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. in the resected polyps Polyps A tumor with a small flap that attaches itself to the wall of various vascular organs such as the nose, uterus and rectum. Polyps bleed easily, and if they are suspected to be cancerous they should be surgically removed. . This approach could be extended to other organs." Dr. Gonnene continued, "Currently, we address multibillion-dollar opportunities with the specimens we know our Mabs are effective against. This new opportunity would allow us to cast an even wider net and we are very excited about the possibility of helping these patients." Studies have already begun at AZ Sint Lucas Hospital, and all scientific results will remain a property of MabCure. About AZ Sint Lucas Hospital The Saint Lucas General Hospital in Bruges is an independent hospital with emphasis on advanced patient care, active clinical research and participation in multi-center clinical trials. About MabCure Inc. MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable cur·a·ble adj. Capable of being cured or healed. . For further information visit the Company's website www.mabcure.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement This news release contains "forward-looking statements". Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company or the University and the inability of the Company or the University to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company or the University assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion